PrimeraDx Launches the Only System Capable of Simultaneous Quantification of mRNA, microRNA and DNA

MANSFIELD, Mass., Aug. 23, 2011 /PRNewswire/ — PrimeraDx today announced the launch of the ICEPlex® system, the only instrument on the market used for simultaneous detection and quantification of disparate target types, such as mRNA, miRNA, SNPs and DNA“We are excited to have launched the ICEPlex, a quantitative multiplex PCR platform,” stated President and CEO Matthew McManus, MD, PhD.   “No longer will users have to rely on semi-quantitative multiplex solutions.  The ability to take one slice of tissue, extract the nucleic acids, and in one well, in parallel, look at mRNA expression, microRNA expression and SNPs is very powerful.”

PrimeraDx has developed an open platform enabling clinical labs to easily develop cost-effective, high impact molecular diagnostic tests.  The ICEPlex instrument has already been placed with a number of key accounts, including large academic research centers, reference laboratories and bio-pharmaceutical companies.   The ICEPlex instrument has a simple workflow and comes with on-board software for assay design, data analysis and reporting.

“It is very exciting to have this innovative platform from PrimeraDx.  As far as I know, this is the only platform that allows you to assay multiple target types, like mRNA, miRNA and SNPs, in a single well,” commented Andrew Schade, MD, PhD, Senior Director of Lilly Clinical Diagnostics Laboratory.  “The ICEPlex system is already changing the way we approach assay development, allowing us to create innovative solutions that were previously not possible.”

About PrimeraDx

PrimeraDx is dedicated to the high growth field of molecular diagnostics.  The Company has developed a unique platform for high-multiplex, quantitative, real-time PCR based on its proprietary STAR technology, implemented on the walk-away ICEPlex instrument system.  PrimeraDx is developing a broad range of applications in oncology, infectious disease, companion diagnostics and multiple non-clinical molecular markets, both through its own efforts and in collaboration with partners.  The Company is backed by a strong group of experienced venture-capital investors, including Abingworth, InterWest Partners, CHL Medical Partners, and Malaysia Technology Development Corporation.  The Company’s website is: www.primeradx.com or www.multiplexpcr.com.

CONTACT: Andrew Bond, +1-508-618-2752, abond@primeradx.com

SOURCE PrimeraDx